These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15613060)

  • 21. PACSIN2 accelerates nephrin trafficking and is up-regulated in diabetic kidney disease.
    Dumont V; Tolvanen TA; Kuusela S; Wang H; Nyman TA; Lindfors S; Tienari J; Nisen H; Suetsugu S; Plomann M; Kawachi H; Lehtonen S
    FASEB J; 2017 Sep; 31(9):3978-3990. PubMed ID: 28550045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy.
    Lear W; Ruzicka M; Leenen FH
    Am J Physiol; 1997 Aug; 273(2 Pt 2):H641-6. PubMed ID: 9277479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
    Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
    Lee EY; Kim GT; Hyun M; Kim S; Seok S; Choi R; Lee MY; Chung CH
    Nephrol Dial Transplant; 2012 Nov; 27(11):4069-79. PubMed ID: 22892126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
    Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
    Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
    Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
    Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the angiotensin-converting enzyme inhibitor quinapril on renal function in rats.
    Graziano MJ; Dethloff LA; Griffin HE; Pegg DG
    Arch Int Pharmacodyn Ther; 1993; 324():87-104. PubMed ID: 8297189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.
    Ruggenenti P; Mosconi L; Sangalli F; Casiraghi F; Gambara V; Remuzzi G; Remuzzi A
    Kidney Int; 1999 Mar; 55(3):984-94. PubMed ID: 10027935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker.
    Wang G; Lai FM; Lai KB; Chow KM; Kwan BC; Li PK; Szeto CC
    Eur J Endocrinol; 2008 Mar; 158(3):317-22. PubMed ID: 18299464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiotensin-converting enzyme inhibition.
    Clerk LH; Vincent MA; Barrett EJ; Lankford MF; Lindner JR
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1804-9. PubMed ID: 17911341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
    Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss.
    Wang G; Lai FM; Lai KB; Chow KM; Kwan BC; Li KT; Szeto CC
    Ren Fail; 2010 Jan; 32(3):372-9. PubMed ID: 20370455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrauterine growth restriction leads to a dysregulation of Wilms' tumour supressor gene 1 (WT1) and to early podocyte alterations.
    Menendez-Castro C; Hilgers KF; Amann K; Daniel C; Cordasic N; Wachtveitl R; Fahlbusch F; Plank C; Dötsch J; Rascher W; Hartner A
    Nephrol Dial Transplant; 2013 Jun; 28(6):1407-17. PubMed ID: 23229934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
    Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
    Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
    Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
    Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
    J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Urinary Excretion of Podocyte Markers in Normoalbuminuric Patients with Diabetes.
    Lioudaki E; Stylianou KG; Petrakis I; Kokologiannakis G; Passam A; Mikhailidis DP; Daphnis EK; Ganotakis ES
    Nephron; 2015; 131(1):34-42. PubMed ID: 26340089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.
    Davis BJ; Johnston CI; Burrell LM; Burns WC; Kubota E; Cao Z; Cooper ME; Allen TJ
    Diabetologia; 2003 Jul; 46(7):961-71. PubMed ID: 12838387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin-converting enzyme inhibition attenuates arterial constrictor responses in experimental hypertension.
    Kähönen M; Mäkynen H; Wu X; Arvola P; Pekki A; Pörsti I
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1701-9. PubMed ID: 8667241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.